Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

90
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
90
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

154
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
154
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

71
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
71
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

105
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
105
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.2K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.2K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Collecting Metabolite Pharmacokinetics in Drug-Drug Interaction Studies: A Review of Industry Practices and Data Utilization.

Clinical pharmacokinetics·2026
Same author

Depression severity and efficacy outcomes: post hoc analyses from a phase 3 trial of esmethadone for the adjunctive treatment of major depressive disorder with inadequate response to standard antidepressants.

International clinical psychopharmacology·2026
Same author

A First-in-Human, Single- and Multiple-Dose Study of APG777, a Half-Life-Extended Anti-IL-13 Monoclonal Antibody, in Healthy Volunteers.

Clinical and translational science·2025
Same author

Matching in Organ Impairment Studies: A Systematic Review of Accepted Methodologies.

The AAPS journal·2025
Same author

A Comparison of Two Methods for Adaptive Multi-Arm Two-Stage Design.

Statistics in medicine·2025
Same author

Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach.

British journal of clinical pharmacology·2025

Related Experiment Video

Updated: Dec 2, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

Pharmacology-Guided Rule-Based Adaptive Dose Escalation in First-in-Human Studies.

Ewoud-Jan van Hoogdalem1, Mattheus Thijs van Iersel1, Erica Winter2

  • 1PRA Health Sciences, Scientific Affairs - Clinical Pharmacology, Groningen, The Netherlands.

Clinical Pharmacology and Therapeutics
|November 5, 2020
PubMed
Summary

This adaptive dose escalation design optimizes participant use in early drug trials. It reduces participant numbers while maintaining safety and efficiency, unlike standard fixed-size cohorts.

More Related Videos

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Related Experiment Videos

Last Updated: Dec 2, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

6.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Area of Science:

  • Clinical Pharmacology
  • Drug Development
  • Biostatistics

Background:

  • First-in-human (FIH) studies traditionally use fixed-size cohorts for dose escalation.
  • This approach may expose participants to suboptimal or irrelevant dose levels.
  • Optimizing participant allocation is crucial for efficient early drug evaluation.

Purpose of the Study:

  • To present and evaluate a novel pharmacology-guided, rule-based adaptive dose escalation design for FIH studies.
  • To assess the design's ability to minimize participant exposure to irrelevant doses and maximize the use of participants.
  • To compare the adaptive design's performance against conventional methods in terms of safety and efficiency.

Main Methods:

  • Developed a paper-based, rule-based adaptive dose escalation design.
  • Utilized criteria including dose-limiting adverse event rates and target exposure/pharmacodynamics.
  • Retrospectively tested the design on 40 FIH studies and prospectively simulated trials with three compounds.

Main Results:

  • The adaptive design showed no overshooting of actual top doses in retrospective analysis.
  • A median reduction of 38% in total participants per study was observed.
  • Simulations indicated comparable safety and efficacy to the 6+2 design but with reduced study size for acceptable therapeutic windows.

Conclusions:

  • The proposed adaptive dose escalation design effectively optimizes participant utilization in FIH studies.
  • It achieves efficiency gains without compromising participant safety.
  • This design offers a valuable alternative to traditional fixed-cohort approaches in early clinical drug development.